反応式
[CH3:1][O:2][C:3]1[CH:18]=[CH:17][C:6]([O:7][C:8]2[CH:13]=[CH:12][C:11]([C:14](=O)[CH3:15])=[CH:10][CH:9]=2)=[CH:5][CH:4]=1.BrC(Br)=O.[NH2:23][C:24]1[CH:33]=[C:32]2[C:27]([CH2:28][CH2:29][N:30](C(OC(C)(C)C)=O)[CH2:31]2)=[CH:26][CH:25]=1.N[C:42]([NH2:44])=O.[C:45]([Cl:51])(=O)[CH2:46][CH2:47][CH2:48]C.N1C=CN=C1>>[ClH:51].[CH2:45]([C:42]1[N:23]([C:24]2[CH:33]=[C:32]3[C:27]([CH2:28][CH2:29][NH:30][CH2:31]3)=[CH:26][CH:25]=2)[CH:15]=[C:14]([C:11]2[CH:12]=[CH:13][C:8]([O:7][C:6]3[CH:17]=[CH:18][C:3]([O:2][CH3:1])=[CH:4][CH:5]=3)=[CH:9][CH:10]=2)[N:44]=1)[CH2:46][CH2:47][CH3:48]参加物
7
反応物 6
生成物 1
実験手順
1-[4-(4-methoxyphenoxy)phenyl]ethan-1-one (1 mmol) was brominated by General Procedure R1. The bromo ketone was condensed with 7-amino-2-Boc-1,2,3,4-tetrahydroisoquinoline following general procedure R2. The aminoketone intermediate was treated with n-pentanoyl chloride accoding to General Procedure R3. The product amide was then subjected to imidazole formation employing general procedure R4. The BOC group of the product was removed employing general procedure T1 to afford 7-{2-butyl-4-[4-(4-methoxy-phenoxy)-phenyl]-imidazol-1-yl}-1,2,3,4-tetrahydro-isoquinoline hydrochloride (yield 135 mg)
後処理
- customThe BOC group of the product was removed
出典と根拠
- ORDレコード
- ord-f2ab40e73e5c4a46b8f5db2675ce8fd1
- 出典データセット
- uspto-grants-2010_06
- 特許番号
- US07737285B2
関連ノート
読み込み中…